Idarucizumab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Idarucizumab |
| DrugBank ID | DB09264 |
| Brand Names (EU) | Praxbind |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 95.66% |
Approved Indication (EMA)
Praxbind is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required: for emergency surgery/urgent procedures; in life-threatening or uncontrolled bleeding.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | hemoglobinopathy | 95.66% | DL |
| 2 | rheumatoid arthritis | 95.52% | DL |
| 3 | partial deletion of the short arm of chromosome 16 | 95.00% | DL |
| 4 | beta-thalassemia with other manifestations | 94.98% | DL |
| 5 | pyruvate kinase deficiency of red cells | 94.82% | DL |
| 6 | hemolytic anemia due to glucophosphate isomerase deficiency | 94.56% | DL |
| 7 | pyropoikilocytosis, hereditary | 94.26% | DL |
| 8 | bronchitis | 94.09% | DL |
| 9 | gout | 93.75% | DL |
| 10 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | 93.62% | DL |
| 11 | osteoarthritis | 93.49% | DL |
| 12 | antithrombin deficiency type 2 | 92.76% | DL |
| 13 | osteoarthritis susceptibility | 92.71% | DL |
| 14 | heparin cofactor 2 deficiency | 92.67% | DL |
| 15 | factor 5 excess with spontaneous thrombosis | 92.55% | DL |
| 16 | brachydactyly-syndactyly syndrome | 92.21% | DL |
| 17 | pseudoachondroplasia | 91.53% | DL |
| 18 | thrombophilia | 91.36% | DL |
| 19 | hepatic porphyria | 90.95% | DL |
| 20 | myocardial infarction | 90.84% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.